Empagliflozin reduces brain pathology in Alzheimer's disease and type 2 diabetes

被引：0

作者：

Carmen Hierro-Bujalance ^{[1
,2
,3
]}

Monica Garcia-Alloza ^{[1
,2
]}

机构：

[1] Division of Physiology, School of Medicine,Universidad de Cadiz

[2] Instituto de Investigacion e Innovacion en Ciencias Biomedicas de la Provincia de Cadiz (INIBICA)

[3] Salus Infirmorum-Universidad de Cadiz

来源：

Neural Regeneration Research | 2024年 / 06期

关键词：

D O I：

暂无

中图分类号：

R749.16 [];

学科分类号：

100203 ;

摘要：

Alzheimer’s disease(AD) and type 2 diabetes(T2D): More than 55 million people suffer from dementia, and it is expected that over 150 million people will suffer from this disease by 2050. AD is the most common type of dementia and while aging remains the main risk factor to suffer it, previous studies have also shown that metabolic disorders, and T2D specifically, are also major contributors(Wang et al., 2012).

引用

页码：1189 / 1190

页数：2

共 13 条

[1]

Pawlos Agnieszka,Broncel Marlena,Woźniak Ewelina,Markiewicz Łukasz,PiastowskaCiesielska Agnieszka,GorzelakPabiś Paulina.SGLT2 Inhibitors May Restore Endothelial Barrier Interrupted by 25-Hydroxycholesterol[J].Molecules,2023

[2]

Ahmad Ehtasham,Lim Soo,Lamptey Roberta,Webb David R,Davies Melanie J.Type 2 diabetes[J].Lancet (London, England),2022

[3]

Hardy John,de Strooper Bart,EscottPrice Valentina.Diabetes and Alzheimer's disease: shared genetic susceptibility?[J].The Lancet. Neurology,2022

[4]

Reich Niklas,Hölscher Christian.The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review[J].Frontiers in Neuroscience,2022

[5] Empagliflozin nanoparticles attenuates type2 diabetes induced cognitive impairment via oxidative stress and inflammatory pathway in high fructose diet induced hyperglycemic mice [J].

Khan, Tahira ;

Khan, Sana ;

Akhtar, Mohd ;

Ali, Javed ;

Najmi, Abul Kalam .

NEUROCHEMISTRY INTERNATIONAL, 2021, 150

[6] Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes [J].

Hierro-Bujalance, Carmen ;

Infante-Garcia, Carmen ;

del Marco, Angel ;

Herrera, Marta ;

Carranza-Naval, Maria Jose ;

Suarez, Javier ;

Alves-Martinez, Pilar ;

Lubian-Lopez, Simon ;

Garcia-Alloza, Monica .

ALZHEIMERS RESEARCH & THERAPY, 2020, 12 (01)

[7] Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway [J].

Amin, Entesar F. ;

Rifaai, Rehab A. ;

Abdel-Latif, Rania G. .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2020, 34 (05) :548-558

[8] Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA- REG OUTCOME Trial [J].

Fitchett, David ;

Inzucchi, Silvio E. ;

Cannon, Christopher P. ;

McGuire, Darren K. ;

Scirica, Benjamin M. ;

Johansen, Odd Erik ;

Sambevski, Steven ;

Kaspers, Stefan ;

Pfarr, Egon ;

George, Jyothis T. ;

Zinman, Bernard .

CIRCULATION, 2019, 139 (11) :1384-1395

[9]

Melvin R. Hayden,DeAna G. Grant,Annayya R. Aroor,Vincent G. DeMarco.Empagliflozin Ameliorates Type 2 Diabetes-Induced Ultrastructural Remodeling of the Neurovascular Unit and Neuroglia in the Female db/db Mouse[J].Brain Sciences,2019

[10] Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice [J].

Lin, Bowen ;

Koibuchi, Nobutaka ;

Hasegawa, Yu ;

Sueta, Daisuke ;

Toyama, Kensuke ;

Uekawa, Ken ;

Ma, MingJie ;

Nakagawa, Takashi ;

Kusaka, Hiroaki ;

Kim-Mitsuyama, Shokei .

CARDIOVASCULAR DIABETOLOGY, 2014, 13

← 1 2 →